Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European liver transplant registry study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00078134" target="_blank" >RIV/00023001:_____/19:00078134 - isvavai.cz</a>

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S0168827819302727?token=232FF6F9A817EE80AEBC04A5604BDE9DC467E7876337FCB17F625DF5C1A339963827369461105DDD1DA1305AA178A04D" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0168827819302727?token=232FF6F9A817EE80AEBC04A5604BDE9DC467E7876337FCB17F625DF5C1A339963827369461105DDD1DA1305AA178A04D</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jhep.2019.04.011" target="_blank" >10.1016/j.jhep.2019.04.011</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European liver transplant registry study

Popis výsledku v původním jazyce

Background &amp; Aims: Little is known about outcomes of liver transplantation for patients with non-alcoholic steatohepatitis (NASH). We aimed to determine the frequency and outcomes of liver transplantation for patients with NASH in Europe and identify prognostic factors. Methods: We analysed data from patients transplanted for endstage liver disease between January 2002 and December 2016 using the European Liver Transplant Registry database. We compared data between patients with NASH versus other aetiologies. The principle endpoints were patient and overall allograft survival. Results: Among 68,950 adults undergoing first liver transplantation, 4.0% were transplanted for NASH - an increase from 1.2% in 2002 to 8.4% in 2016. A greater proportion of patients transplanted for NASH (39.1%) had hepatocellular carcinoma (HCC) than non-NASH patients (28.9%, p &lt;0.001). NASH was not significantly associated with survival of patients (hazard ratio [HR] 1.02, p = 0.713) or grafts (HR 0.99; p = 0.815) after accounting for available recipient and donor variables. Infection (24.0%) and cardio/cerebrovascular complications (5.3%) were the commonest causes of death in patients with NASH without HCC. Increasing recipient age (61-65 years: HR 2.07, p &lt;0.001; &gt;65: HR 1.72, p = 0.017), elevated model for end-stage liver disease score (&gt;23: HR 1.48, p = 0.048) and low (&lt;18.5 kg/m(2): HR 4.29, p = 0.048) or high (&gt;40 kg/m(2): HR 1.96, p = 0.012) recipient body mass index independently predicted death in patients transplanted for NASH without HCC. Data must be interpreted in the context of absent recognised confounders, such as premorbid metabolic risk factors. Conclusions: The number and proportion of liver transplants performed for NASH in Europe has increased from 2002 through 2016. HCC was more common in patients transplanted with NASH. Survival of patients and grafts in patients with NASH is comparable to that of other disease indications. Lay summary: The prevalence of non-alcoholic fatty liver disease has increased dramatically in parallel with the worldwide increase in obesity and diabetes. Its progressive form, non-alcoholic steatohepatitis, is a growing indication for liver transplantation in Europe, with good overall outcomes reported. However, careful risk factor assessment is required to maintain favourable post-transplant outcomes in patients with nonalcoholic steatohepatitis. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V.

Název v anglickém jazyce

Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European liver transplant registry study

Popis výsledku anglicky

Background &amp; Aims: Little is known about outcomes of liver transplantation for patients with non-alcoholic steatohepatitis (NASH). We aimed to determine the frequency and outcomes of liver transplantation for patients with NASH in Europe and identify prognostic factors. Methods: We analysed data from patients transplanted for endstage liver disease between January 2002 and December 2016 using the European Liver Transplant Registry database. We compared data between patients with NASH versus other aetiologies. The principle endpoints were patient and overall allograft survival. Results: Among 68,950 adults undergoing first liver transplantation, 4.0% were transplanted for NASH - an increase from 1.2% in 2002 to 8.4% in 2016. A greater proportion of patients transplanted for NASH (39.1%) had hepatocellular carcinoma (HCC) than non-NASH patients (28.9%, p &lt;0.001). NASH was not significantly associated with survival of patients (hazard ratio [HR] 1.02, p = 0.713) or grafts (HR 0.99; p = 0.815) after accounting for available recipient and donor variables. Infection (24.0%) and cardio/cerebrovascular complications (5.3%) were the commonest causes of death in patients with NASH without HCC. Increasing recipient age (61-65 years: HR 2.07, p &lt;0.001; &gt;65: HR 1.72, p = 0.017), elevated model for end-stage liver disease score (&gt;23: HR 1.48, p = 0.048) and low (&lt;18.5 kg/m(2): HR 4.29, p = 0.048) or high (&gt;40 kg/m(2): HR 1.96, p = 0.012) recipient body mass index independently predicted death in patients transplanted for NASH without HCC. Data must be interpreted in the context of absent recognised confounders, such as premorbid metabolic risk factors. Conclusions: The number and proportion of liver transplants performed for NASH in Europe has increased from 2002 through 2016. HCC was more common in patients transplanted with NASH. Survival of patients and grafts in patients with NASH is comparable to that of other disease indications. Lay summary: The prevalence of non-alcoholic fatty liver disease has increased dramatically in parallel with the worldwide increase in obesity and diabetes. Its progressive form, non-alcoholic steatohepatitis, is a growing indication for liver transplantation in Europe, with good overall outcomes reported. However, careful risk factor assessment is required to maintain favourable post-transplant outcomes in patients with nonalcoholic steatohepatitis. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of hepatology

ISSN

0168-8278

e-ISSN

—

Svazek periodika

71

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

10

Strana od-do

313-322

Kód UT WoS článku

000475462500014

EID výsledku v databázi Scopus

2-s2.0-85066258335